Study details
Enrolling now
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Axsome Therapeutics, Inc.
NCT IDNCT07398417ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Ages
18+
Locations
16 sites in AR, CA, CT +10
What this study is about
This Phase 3 study is focused on people with fibromyalgia.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Musculoskeletal